A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
14/03/2022at 12:46

Russian ambassador to Denmark: Takeover of foreign firms is an option

Russia is considering inserting Russian leadership into foreign companies that have halted activities in the country, according to Vladimir Barbin, the Russian ambassador to Denmark.
Photo: Frank Hoermann/AP/Ritzau Scanpix
by RITZAU, translated by daniel pedersen

Danish companies that have ceased their activities in Russia due to the country’s invasion of Ukraine cannot be confident that their operations can continue when the war is over.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Finn Frandsen/Ritzau Scanpix

    Russian firms now allowed to violate patents from "unfriendly" countries

    For subscribers

  • Photo: Coloplast / PR

    Coloplast doesn't expect impact from potential Russian gas halt

    For subscribers

  • From a legal standpoint, nothing is stopping Sonova, the world’s biggest hearing aid firm, from continuing to sell its products to Russia, says an expert on sanctions | Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

    Sanctions expert: Sonova's sales in Russia are still permitted

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Novo Nordisk operates a factory in Russia, delivering insulin to 700,000 Russian diabetics | Foto: Torben Stroyer/Jyllands-Posten/Ritzau Scanpix
Pharma & biotech

Ukraine to force pharmaceutical firms to discontinue Russian activities

The war-torn country wants to pressure companies into making a choice: Exit Russia or lose market licenses in Ukraine.

For subscribers

Foto: Ambu/pr
Medtech

Ambu silent on Russian exit issues

In December, Ambu CEO Britt Meelby Jensen briefly noted that shutting down Russian activities was not going according to plan – and she does not want to say more than that today.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Commercial Director

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Principal Laboratory Technologist

  • Experienced Patent Counsel

  • Application Manager

  • Application Manager

See all jobs

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Commercial Director

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Principal Laboratory Technologist

  • Experienced Patent Counsel

  • Application Manager

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge